C3 AI Reinvents No Code AI with the Introduction of C3 AI Ex Machina
C3 AI (NYSE: AI), the world’s leading provider of enterprise AI software, today announced the general availability of C3 AI® Ex Machina, a next-generation predictive analytics application that empowers anyone to develop, scale, and produce AI-based insights without writing code.
Analysts, operators, and subject matter experts across all industries and business functions are increasingly required to develop predictive and prescriptive insights compiled from vast and disparate datasets. While there are many no-code tools available that lower the barrier for users to build ML models and perform data analysis, none provide end-to-end capabilities that enable them to capture and process the volume and variety of data required, automatically generate interpretable AI models, and productize, deploy, and scale the results across their company. Current predictive analytics tools are typically complicated to use and limit the ability of their insights to drive real business outcomes.
C3 AI Ex Machina is the only end-to-end, no-code predictive analytics solution that enables individuals, teams, and enterprises to:
- Rapidly and flexibly access and prep petabytes of disparate data with prebuilt connectors to data sources such as Snowflake, S3, ADLS, Databricks, and more.
- Build and manage AI models without writing code using an intuitive drag-and-drop interface supported by powerful AutoML.
- Drive company-wide results by seamlessly publishing predictive insights to enterprise systems or custom business applications.
- Scale cloud resources to meet needs in a modern, cloud-native application while only paying for resources used.
- Grow with confidence by integrating and expanding on the C3 AI Suite, the platform that powers billions of AI predictions for the world’s largest companies.
Con Edison’s data analysts use C3 AI Ex Machina to identify malfunctioning meters in near-real-time, realizing significant business value. "C3 AI Ex Machina empowers our analysts to easily harness all our data and assess reliability and safety risks. Our AMI Operations group recently used C3 AI Ex Machina to build predictive models that identified hazardous electric meters at risk of overheating. Using C3 AI Ex Machina, our business analysts are now able to evaluate near-real-time risk scores and immediately schedule prioritized field inspections,” said Chris Brownlee, Department Manager at Con Edison. “C3 AI Ex Machina has dramatically simplified and accelerated our ability to build and deploy machine learning models to address use cases that proactively identify risks and provide safer, more reliable service to our customers.”
C3 AI Ex Machina enables anyone to apply the power of predictive analytics to their business and play a role in the increasing digitization of company operations. The application allows users to solve a limitless range of complex use cases, including customer churn prevention, supplier delay mitigation, asset reliability prediction, and fraud detection – all supported by the robust platform enterprise AI capabilities of the C3 AI Suite.
“C3 AI Ex Machina enables anyone to combine their business expertise with no-code AI to deliver predictive insights that their company can take informed action against,” said C3 AI President and CTO Ed Abbo. “C3 Ex Machina offers a tried, tested, and proven path to rapid enterprise AI application development and deployment. It empowers anyone with subject matter expertise to significantly improve their organization’s ability to make timely and contextual data-driven decisions.”
Learn more about C3 AI Ex Machina and try the application at https://c3.ai/products/c3-ai-ex-machina/.
About C3 AI
C3 AI (NYSE:AI) is a leading provider of Enterprise AI software for accelerating digital transformation. C3 AI delivers a family of fully integrated products: C3 AI® Suite, an end-to-end platform for developing, deploying, and operating large-scale AI applications; C3 AI Applications, a portfolio of industry-specific SaaS AI applications; C3 AI CRM, a suite of industry-specific CRM applications designed for AI and machine learning; and C3 AI Ex Machina, a no-code AI solution to apply data science to everyday business problems. The core of the C3 AI offering is an open, model-driven AI architecture that dramatically simplifies data science and application development. Learn more at: www.c3.ai
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210127005302/en/
Contact information
C3 AI Public Relations
Edelman
Lisa Kennedy
415-914-8336
pr@c3.ai
Investor Relations
IR@C3.ai
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SCENTMATIC's AI "KAORIUM" Debuts at THAMEEN Fragrance Launch in London's Selfridges4.7.2025 12:13:00 EEST | Press release
SCENTMATIC Inc., a leader in scent digitalization, introduced its AI-powered scent-to-language system, KAORIUM, at the THAMEEN Fragrance new product launch event. This pivotal event took place from June 5 to 11, 2025, at Selfridges department store in London, UK. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250703662207/en/ State of exhibition Global Expansion: KAORIUM Establishes UK Presence Europe leads the global fragrance market, with the UK projected to reach US$2.82 billion by 2033. Recognizing this, SCENTMATIC is rapidly expanding its international footprint. In May 2024, SCENTMATIC established its overseas subsidiary, KAORIUM, in London, appointing industry expert Ben Yanoushek as CEO. Official UK operations commenced on February 1, 2025, with the launch of its dedicated website: www.kaorium.com. KAORIUM Trialed at "Florentine Diamond" Launch Event The "Florentine Diamond" launch event for luxury brand THAMEEN Frag
Global Tourism Surging Ahead of Economic Growth, With Visits to Hit 30 Billion by 20344.7.2025 02:00:00 EEST | Press release
The World Economic Forum has today published a new report forecasting that the travel and tourism industry is projected to serve 30 billion tourist trips by 2034. Travel and Tourism at a Turning Point: Principles for Transformative Growth, produced in collaboration with Kearney and the Ministry of Tourism Saudi Arabia, reveals a projected $16 trillion contribution to global GDP by the same year—representing more than 11% of the total world economy, according to World Travel & Tourism Council estimates. The report also found that the sector is expanding 1.5 times faster than the global economy, generating significant commercial opportunities as long as the mounting challenges of climate change, labour shortages and infrastructure gaps are addressed. Inbound and outbound trips increasing fast Asia is on track to become the world’s fastest-growing tourism economy, with the direct travel and tourism GDP contribution expected to exceed 7% across the region by 2034. Notably, India and China
The 2025-2026 World Branding Awards Animalis Edition Honouring Leading Pet and Animal Brands Globally3.7.2025 22:00:00 EEST | Press release
The 2025-2026 World Branding Awards Animalis Edition marked its fifth instalment, bringing together leading pet and animal brands from all around the world. These brands were celebrated for their outstanding achievements, earning recognition as National, Regional, and Global Winners. The awards ceremony, held at Vienna's prestigious Hofburg Palace, welcomed winners across diverse categories, including pet food, retail, wellness, pet exhibitions, and aquatic products. Mounia Berrada-Gouzi expertly hosted the evening, which culminated in a grand celebration of brand excellence. “The Animalis Edition of the World Branding Awards recognises brands that have achieved the highest distinction—genuine recognition in the hearts and minds of consumers. Tonight, we honour those whose names resonate globally, whose values inspire loyalty, and whose presence defines excellence in the pet and animal industry,” said Richard Rowles, Chairman of the World Branding Forum. Out of over 950 brands nominate
Venture Global Announces 20-Year Sales and Purchase Agreement with PETRONAS3.7.2025 15:59:00 EEST | Press release
Today, Venture Global, Inc. (NYSE: VG) announced the execution of a new 20-year Sales and Purchase Agreement (SPA) with PETRONAS LNG Ltd. (PLL), a subsidiary of the Malaysian state-owned oil and gas company, PETRONAS. Under the terms of the SPA, PETRONAS will purchase 1 million tonnes per annum (MTPA) of liquefied natural gas (LNG) from Venture Global’s third facility, CP2 LNG, for 20 years. This builds upon Venture Global’s existing agreement with PETRONAS for 1 MTPA of LNG supply from Plaquemines LNG. PETRONAS, a world-class partner in the LNG industry, joins other CP2 LNG customers in Europe, Asia and the rest of the world in a strategically important project to global energy supply and security. To date, approximately 10.75 MTPA of the 14.4 MTPA nameplate capacity for CP2 Phase One has been sold. About Venture Global Venture Global is a long-term, low-cost provider of U.S. LNG sourced from resource rich North American natural gas basins. Venture Global’s business includes assets ac
Frost & Sullivan Recognizes Novotech as 2025 Global Biotech CRO Company of the Year3.7.2025 15:05:00 EEST | Press release
In recognition of its innovation, client-focused delivery, and global impact, Novotech has been awarded the 2025 Global Biotechnology Contract Research Organization (CRO) Company of the Year by Frost & Sullivan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250703950144/en/ Novotech Wins Global CRO Award Novotech is a globally recognized full-service clinical CRO and scientific advisory firm, trusted by biotech and small- to mid-sized pharmaceutical companies to advance their drug development programs at every phase. With a global footprint spanning Asia-Pacific, North America, and Europe, Novotech supports over 5,000 clinical trial sites and a distributed team of experts delivering seamless, end-to-end solutions across geographies. “Novotech is redefining biotech-focused clinical research through AI-driven innovation, global expansion, and a client-embedded partnership model. With a clear vision to be the CRO of choice for
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom